Monographie - Ceftazidime Avibactam

Pēdējā atjaunošana :
19/11/2024

Ceftazidime Avibactam

Ķīmiskā uzbūve

Oriģinālais nosaukums

Tirdzniecības nosaukumi ir apzīmējoši un palīgvielas var atšķirties dažādām valstīm un laboratorijām

Avycaz	Amerikas Savienotās Valstis
Torgena	Brazīlija
Zavicefta	Amerikas Savienotās Valstis, Argentīna, Austrālija, Beļģija, Čīle, Francija, Īrija, Itālija, Lielbritānija, Luksemburga, Meksika, Norvēģija, Peru, Rumānija, Slovēnija, Somija, Spānija, Šveice, Tunisija, Ungārija, Vācija, Zviedrija

Literatūras saraksts : Ceftazidime Avibactam

	tips	publicēšana
2902	Laboratorija	Ceftazidime - avibactam (Avycaz®) - Summary of Product Characteristics Forrest Pharmaceuticals 2015
3520	Laboratorija	Cidomycin - Summary of product Chracteristics. Sanofi 2011
3549	Laboratorija	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3643	Laboratorija	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Laboratorija	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3984	Žurnāls	Meyer K, Santarossa M, Danziger L.H, Wenzler E. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water. Hosp Pharm 2017 ,52;3 : 221-228
4055	Žurnāls	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Žurnāls	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4434	Žurnāls	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4528	Žurnāls	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4548	Žurnāls	O'Donnell J.N, Xu A, Lodise T.P. Intravenous Compatibility of Ceftazidime/Avibactam and Aztreonam Using Simulated and Actual Y-site Administration. Clin Ther 2020 ; 42, 8: 1580-1586.
4634	Žurnāls	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4801	Žurnāls	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4822	Žurnāls	Naicker S, Roberts J.A, Won H, Wallis S.C, Unwin S, Jamieson C, Hills T, Gilchrist M, Santillo M, Seaton R.A, Drummond F, Sime Evaluation of the stability of ceftazidime/avibactam in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy utilizing a national stability protocol framework. JAC Antimicrob Resist 2024

Mentions Légales